The research laboratory of William C. Strohsnitter, DSc is focused on examining cancer risk factors in women in partnership with Tufts Medical Center's Division of Gynecologic Oncology in Boston, MA.
The Diethylstilbestrol (DES) Follow-up Study
Strohsnitter and Brian Bond, MD are currently leading a follow up study to the investigation between prenatal DES exposure and cancer incidence.
DES was an estrogen analog prescribed to pregnant women predominantly between 1940 and 1960 for a host of indications. In 1971, prenatal DES exposure was associated with Vaginal and Cervical Clear Cell Adenoma development. Since 1975, the DES Follow-up Study has been investigating the association between prenatal DES exposure and cancer in men, women, and more recently in women whose mothers were prenatally DES exposed (Third Generation Study). Drs. Stohsnitter and Bond are currently focused on understanding the incidence of cancer among men who were prenatally exposed to DES .
Prenatal and Perinatal Breast Cancer Risk Factors and Umbilical Cord Stem Cells
Strohsnitter is also collaborating with the Department of Cancer Biology at the University of Massachusetts on projects investigating the association between factors suspected to influence adult breast cancer risk and umbilical cord stem cell number.
For example, the research team recently completed a project funded by the National Cancer Institute to investigate whether preeclamptic pregnancy, high birth weight, and prenatal cigarette smoke exposure are associated with umbilical cord stem cell number, which, in turn, may also correlate to adult breast cancer risk.